Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Resiquimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 known ✓ | Q9NYK1 | 19/20 | 1.00 |
| ▸ | TLR8 known ✓ | Q9NR97 | 12/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resiquimod SCHEMBL34159 | 1.00 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL21352711 | 1.00 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2266073 | 0.99 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2262583 | 0.99 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| SCHEMBL24880278 | 0.94 | TLR7 (0.88) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL22158700 | 0.93 | TLR7 (0.86) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL17190806 | 0.93 | TLR7 (0.86) | TLR7TLR8NUDT1 | |
| SCHEMBL6718996 | 0.92 | TLR7 (0.84) | TLR7TLR8NUDT1 | |
| SCHEMBL20199817 | 0.91 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| SCHEMBL5454764 | 0.90 | TLR7 (0.82) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360199-A1 | IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE | US HEALTH (US) | 2025-11-27 | — | — | US | claimed |
| EP-4551247-A1 | IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-05-14 | — | — | EP | claimed |
| CN-119325392-A | Phenyl maleimide linker | 萤火虫生物股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| EP-4487869-A2 | RNA ENCODING A TUMOR ANTIGEN | CureVac SE (DE) | 2025-01-08 | — | — | EP | claimed |
| WO-2024143876-A1 | NANOPARTICLES FOR PHOTOIMMUNE THERAPY COMPRISING PHOTOSENSITIZER AND ADJUVANT, AND USAGE THEREOF | 한국과학기술연구원 | 2024-07-04 | — | — | WO | claimed |
| US-20240091344-A1 | MERS CORONAVIRUS VACCINE | CureVac SE (DE) | 2024-03-21 | — | — | US | claimed |
| CN-117653720-A | Extraction method of antigen component, delivery particle containing antigen component and application of delivery particle | 苏州尔生生物医药有限公司 | 2024-03-08 | — | — | CN | claimed |
| WO-2024011033-A1 | IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-01-11 | — | — | WO | claimed |
| US-20230407258-A1 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | FIGENE, LLC | 2023-12-21 | — | — | US | claimed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | claimed |
| US-20220401541-A1 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | FIBROBIOLOGICS, INC. | 2022-12-22 | — | — | US | claimed |
| US-20220401554-A1 | USE OF MEMBRANE INHIBITORS TO ENHANCE VACCINE DEVELOPMENT AGAINST ENVELOPED VIRUSES | CORNELL UNIVERSITY | 2022-12-22 | — | — | US | claimed |
| EP-4051305-A1 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | Figene, LLC (US) | 2022-09-07 | — | — | EP | claimed |
| US-20220235324-A1 | MULTIPLE ANTIGEN SPECIFIC CELL THERAPY METHODS | HRYZ (SHANGHAI) BIOTECH CO. (CN) | 2022-07-28 | — | — | US | claimed |
| EP-4031167-A1 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | Figene, LLC (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220213135-A1 | DERIVATIVES OF GLYCERO-MANNO-HEPTOSE PHOSPHATE AND THEIR USE IN MODULATING AN IMMUNE RESPONSE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2022-07-07 | — | — | US | claimed |
| US-20220211842-A1 | Methods and Devices for the Treatment of Food Allergies | TEXAS TECH UNIVERSITY SYSTEM | 2022-07-07 | — | — | US | claimed |
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2022-06-09 | — | — | US | claimed |
| EP-3980080-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| EP-3959220-A1 | DERIVATIVES OF GLYCERO-MANNO-HEPTOSE PHOSPHATE AND THEIR USE IN MODULATING AN IMMUNE RESPONSE | Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) | 2022-03-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401554-A1 | USE OF MEMBRANE INHIBITORS TO ENHANCE VACCINE DEVELOPMENT AGAINST ENVELOPED VIRUSES | PIGS, VMA21, FURIN | TLR7 390/4885TLR8 1093/4885NUDT1 3740/4885 |
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | GALK1, PHKA1, PGK1 | TLR7 498/4885TLR8 707/4885NUDT1 2474/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | TLR7 210/4885TLR8 87/4885NUDT1 2396/4885 |
| US-20240091344-A1 | MERS CORONAVIRUS VACCINE | SARS1, RNMT, ACE2 | TLR7 320/4885TLR8 1180/4885NUDT1 4221/4885 |
| US-20220213135-A1 | DERIVATIVES OF GLYCERO-MANNO-HEPTOSE PHOSPHATE AND THEIR USE IN MODULATING AN IMMUNE RESPONSE | GALK1, PGK1, PHKA1 | TLR7 757/4885TLR8 1114/4885NUDT1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.